PD32-05 PHASE I CLINICAL STUDY ON THE COMBINATION THERAPY OF CHP-NY-ESO-1 CANCER VACCINE AND MIS416 FOR THE TREATMENT OF PATIENTS WITH NY-ESO-1 EXPRESSING REFRACTORY UROTHELIAL CANCER OR CASTRATION-RESISTANT PROSTATE CANCER

Authors :: Takeshi Sasaki
Yoshiki Sugimura
Hiroshi Shiku
Naozumi Harada
Mikiya Ishihara
Norihito Soga
Yoshihiro Miyahara
Shinichi Kageyama
Yasuhide Hori
Hideki Kanda
Source :: Journal of Urology. 195
Publication Year :: 2016
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2016.

Subjects :: Oncology
medicine.medical_specialty
Combination therapy
business.industry
Urology
Cancer
Castration resistant
medicine.disease
Clinical study
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Refractory
Internal medicine
medicine
Cancer vaccine
NY-ESO-1
business
030215 immunology

Full Text Access

Tools